Keypath Education International Inc (ASX:KED) has reported Q4 FY23 revenue of $32.4 million, which is 6.0% higher than Q4 FY22. The company’s FY23 revenue amounted to $124.2 million, a 4.9% increase compared to FY22. The adjusted EBITDA loss for FY was $9.4 million.

Calidus Resources Ltd (ASX:CAI) reported that its Warrawoona Gold Project met guidance for the half year, with 31,364 ounces of gold produced at an all-in sustaining cost (AISC) of A$2,172 per ounce. The company expects production to be weighted towards the second half of the year due to a mill shutdown in the first quarter and access to higher-grade ore in the second half.

Mineral Commodities Ltd (ASX:MRC) has announced the appointment of Scott Lowe as Chief Executive Officer.

Chrysos Corporation (ASX:C79) reported unaudited total revenue of A$8.6M for the quarter, up 27% compared to the previous quarter. The company expects its EBITDA for FY23 to surpass the forecast of A$3.2M. Additionally, Chrysos Corporation forecasts a total revenue range of A$48M to A$58M and an EBITDA range of A$7M to A$17M for FY24.

Raiz Invest Ltd (ASX:RZI) posted total normalised revenue for the Raiz Platform in the June quarter at A$4.4M, which is up 3.1% compared to the previous corresponding period (PCP).

DY6 Metals Ltd (ASX:DY6) has announced the appointment of Lloyd Kaiser as Chief Executive Officer.

QuickFee Ltd (ASX:QFE) reported a Q4 FY23 revenue of A$4.3 million, compared to A$3.5 million in the previous year.

The company expects demand to remain strong despite more challenging economic conditions in Australia.

Botanix Pharmaceuticals has received firm commitments for a A$12.5 million institutional placement. The issue price of the new share is A$0.12 per share.

Medibio Ltd (ASX:MEB) provided an update on its breakthrough device designation with the US FDA. The company received notification from the FDA stating that MEB-001, in its current form, does not meet the criteria for designation as a breakthrough device. Medibio expects to schedule a pre-submission meeting with the regulatory body during Q4 CY2023.

Mosaic Brands (ASX:MOZ) reported that their store-only comparable sales finished the year up 9.6% on the previous corresponding period (PCP). They expect to achieve approximately A$17 million in EBITDA profit for FY23. However, the company remains cautious for FY24. Mosaic Brands projects total sales of about A$519 million for FY. This news is further covered by MOZ.AX.